Cargando…
Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells
Cold atmospheric plasma (CAP) technology, a relatively novel technique mainly investigated as a stand-alone cancer treatment method in vivo and in vitro, is being proposed for application in conjunction with chemotherapy. In this study, we explore whether CAP, an ionized gas produced in laboratory s...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536419/ https://www.ncbi.nlm.nih.gov/pubmed/33020527 http://dx.doi.org/10.1038/s41598-020-73457-7 |
_version_ | 1783590563505766400 |
---|---|
author | Gjika, Eda Pal-Ghosh, Sonali Kirschner, Megan E. Lin, Li Sherman, Jonathan H. Stepp, Mary Ann Keidar, Michael |
author_facet | Gjika, Eda Pal-Ghosh, Sonali Kirschner, Megan E. Lin, Li Sherman, Jonathan H. Stepp, Mary Ann Keidar, Michael |
author_sort | Gjika, Eda |
collection | PubMed |
description | Cold atmospheric plasma (CAP) technology, a relatively novel technique mainly investigated as a stand-alone cancer treatment method in vivo and in vitro, is being proposed for application in conjunction with chemotherapy. In this study, we explore whether CAP, an ionized gas produced in laboratory settings and that operates at near room temperature, can enhance Temozolomide (TMZ) cytotoxicity on a glioblastoma cell line (U87MG). Temozolomide is the first line of treatment for glioblastoma, one of the most aggressive brain tumors that remains incurable despite advancements with treatment modalities. The cellular response to a single CAP treatment followed by three treatments with TMZ was monitored with a cell viability assay. According to the cell viability results, CAP treatment successfully augmented the effect of a cytotoxic TMZ dose (50 μM) and further restored the effect of a non-cytotoxic TMZ dose (10 μM). Application of CAP in conjunction TMZ increased DNA damage measured by the phosphorylation of H2AX and induced G2/M cell cycle arrest. These findings were supported by additional data indicating reduced cell migration and increased αvβ3 and αvβ5 cell surface integrin expression as a result of combined CAP–TMZ treatment. The data presented in this study serve as evidence that CAP technology can be a suitable candidate for combination therapy with existing chemotherapeutic drugs. CAP can also be investigated in future studies for sensitizing glioblastoma cells to TMZ and other drugs available in the market. |
format | Online Article Text |
id | pubmed-7536419 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-75364192020-10-07 Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells Gjika, Eda Pal-Ghosh, Sonali Kirschner, Megan E. Lin, Li Sherman, Jonathan H. Stepp, Mary Ann Keidar, Michael Sci Rep Article Cold atmospheric plasma (CAP) technology, a relatively novel technique mainly investigated as a stand-alone cancer treatment method in vivo and in vitro, is being proposed for application in conjunction with chemotherapy. In this study, we explore whether CAP, an ionized gas produced in laboratory settings and that operates at near room temperature, can enhance Temozolomide (TMZ) cytotoxicity on a glioblastoma cell line (U87MG). Temozolomide is the first line of treatment for glioblastoma, one of the most aggressive brain tumors that remains incurable despite advancements with treatment modalities. The cellular response to a single CAP treatment followed by three treatments with TMZ was monitored with a cell viability assay. According to the cell viability results, CAP treatment successfully augmented the effect of a cytotoxic TMZ dose (50 μM) and further restored the effect of a non-cytotoxic TMZ dose (10 μM). Application of CAP in conjunction TMZ increased DNA damage measured by the phosphorylation of H2AX and induced G2/M cell cycle arrest. These findings were supported by additional data indicating reduced cell migration and increased αvβ3 and αvβ5 cell surface integrin expression as a result of combined CAP–TMZ treatment. The data presented in this study serve as evidence that CAP technology can be a suitable candidate for combination therapy with existing chemotherapeutic drugs. CAP can also be investigated in future studies for sensitizing glioblastoma cells to TMZ and other drugs available in the market. Nature Publishing Group UK 2020-10-05 /pmc/articles/PMC7536419/ /pubmed/33020527 http://dx.doi.org/10.1038/s41598-020-73457-7 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Gjika, Eda Pal-Ghosh, Sonali Kirschner, Megan E. Lin, Li Sherman, Jonathan H. Stepp, Mary Ann Keidar, Michael Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells |
title | Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells |
title_full | Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells |
title_fullStr | Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells |
title_full_unstemmed | Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells |
title_short | Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells |
title_sort | combination therapy of cold atmospheric plasma (cap) with temozolomide in the treatment of u87mg glioblastoma cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536419/ https://www.ncbi.nlm.nih.gov/pubmed/33020527 http://dx.doi.org/10.1038/s41598-020-73457-7 |
work_keys_str_mv | AT gjikaeda combinationtherapyofcoldatmosphericplasmacapwithtemozolomideinthetreatmentofu87mgglioblastomacells AT palghoshsonali combinationtherapyofcoldatmosphericplasmacapwithtemozolomideinthetreatmentofu87mgglioblastomacells AT kirschnermegane combinationtherapyofcoldatmosphericplasmacapwithtemozolomideinthetreatmentofu87mgglioblastomacells AT linli combinationtherapyofcoldatmosphericplasmacapwithtemozolomideinthetreatmentofu87mgglioblastomacells AT shermanjonathanh combinationtherapyofcoldatmosphericplasmacapwithtemozolomideinthetreatmentofu87mgglioblastomacells AT steppmaryann combinationtherapyofcoldatmosphericplasmacapwithtemozolomideinthetreatmentofu87mgglioblastomacells AT keidarmichael combinationtherapyofcoldatmosphericplasmacapwithtemozolomideinthetreatmentofu87mgglioblastomacells |